Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961753 · ClinicalTrials.gov registry record · Phase 4
Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates
A Phase 4 study, sponsored by OSF Healthcare System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00961753 is a Phase 4 study that was terminated before completion, run by OSF Healthcare System. The registered enrollment target is 10 participants.
The verdict
NCT00961753, a Phase 4 study, was terminated before completion, sponsored by OSF Healthcare System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.
Interventions
- DRUG Standard Ibuprofen
- DRUG optimized ibuprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961753
The ClinicalTrials.gov registry entry for NCT00961753 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSF Healthcare System, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Ibuprofen is the first listed.
NCT00961753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961753 about?
NCT00961753 is a clinical study titled "Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates". The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.
What is the current status of trial NCT00961753?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2009-08. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00961753?
The interventions under investigation include: Standard Ibuprofen (DRUG), optimized ibuprofen (DRUG).
Who is sponsoring clinical trial NCT00961753?
This trial is sponsored by OSF Healthcare System, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.